Vireo Growth (VREOF) Cash from Investing Activities (2020 - 2026)
Vireo Growth (VREOF) posted Cash from Investing Activities of $8.0 million for Q1 2026, up 184.91% sequentially from -$9.4 million in Q4 2025, and up 827.27% YoY from $862745.1 in Q1 2025.
Vireo Growth (VREOF) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Vireo Growth has reported Cash from Investing Activities for 7 years, with the latest figure at $8.0 million in Q1 2026.
- Quarterly Cash from Investing Activities rose 827.27% year-over-year to $8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.9 million (up 318.25% YoY) and the FY2025 annual result came in at $8.8 million, up 207.71% from the prior year.
- Cash from Investing Activities improved to $8.0 million in Q1 2026 per VREOF's latest filing, from -$9.4 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $34.0 million in Q2 2025 and troughed at -$14.8 million in Q3 2025.
- A 5-year average of -$27337.1 and a median of -$1.1 million in 2023 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities tumbled 1423.26% in 2024, then surged 1167.2% in 2025.
- Over 5 years, Cash from Investing Activities stood at -$819539.0 in 2022, then jumped by 79.11% to -$171183.0 in 2023, then sank by 1423.26% to -$2.6 million in 2024, then slumped by 261.33% to -$9.4 million in 2025, then soared by 184.91% to $8.0 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $8.0 million, -$9.4 million, and -$14.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | - |
| 10 | Vireo Growth | 491.44 Mn | 349.14 Mn | 95.30 Mn | -69.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.00 Mn |
| Mar 31, 2026 | 8.00 Mn |
| Dec 31, 2025 | -9.42 Mn |
| Dec 31, 2025 | -9.42 Mn |
| Sep 30, 2025 | -14.76 Mn |
| Sep 30, 2025 | -14.76 Mn |
| Jun 30, 2025 | 34.04 Mn |
| Jun 30, 2025 | 34.04 Mn |
| Mar 31, 2025 | -1.10 Mn |
| Mar 31, 2025 | -1.10 Mn |
| Dec 31, 2024 | -2.61 Mn |
| Dec 31, 2024 | -2.61 Mn |
| Sep 30, 2024 | -1.29 Mn |
| Sep 30, 2024 | -1.29 Mn |
| Jun 30, 2024 | -3.19 Mn |
| Jun 30, 2024 | -3.19 Mn |
| Mar 31, 2024 | -1.05 Mn |
| Mar 31, 2024 | -1.05 Mn |
| Dec 31, 2023 | -171,183.00 |
| Dec 31, 2023 | -171,183.00 |